ESR1 and breast cancer: Results of the phase III EMERALD trial led to multiple regulatory approvals of elacestrant as the first oral selective ER degrader for the treatment of postmenopausal women or adult men with ER+/HER2− ESR1-mutated advanced breast cancer or mBC with disease progression following at least one line of ET (30–32).